Creating Value by Overcoming Treatment Barriers View previous quarters - Today Latest News View all press releases 10.27.26 Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET Read More 10.15.26 Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 Read More 10.14.26 Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film Read More Events View all events Upcoming Events 11.04.26 8:00 AM EST Q3 2026 Aquestive Therapeutics, Inc. Earnings Conference Call Past Events 09.14.26 9:00 AM EDT H.C. Wainwright 28th Annual Global Investment Conference 09.09.26 3:20 PM EDT 2026 Cantor Global Healthcare Conference Fireside Chat Presentations View all presentations Corporate Presentation – September 2026 Anaphylm Human Factors and Clinical Study Supplemental Materials 1.7 MB Anaphylm™ (dibutepinephrine) Sublingual Film Complete Response Letter Supplemental Material 1.1 MB
10.27.26 Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET Read More
10.15.26 Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 Read More
10.14.26 Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film Read More
